MDNA 109 LA2
Alternative Names: MDNA109-LA2Latest Information Update: 28 Oct 2023
At a glance
- Originator Medicenna Therapeutics
- Class Antineoplastics; Interleukins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Interleukin-2 receptor beta subunit agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 25 Sep 2019 Preclinical trials in Cancer in USA (Parenteral)
- 25 Sep 2019 Pharmacodynamics data from a preclinical trial in Cancer presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2019)